Source comparison
CJC-1295 No DAC vs Mod GRF 1-29: Sourcing Comparison
Amino Acid Sequence 29-AA tetrasubstituted GHRH analog (D-Ala2, Gln8, Leu15, Leu27) Identical sequence. No structural difference Plasma Half-Life ~30 minutes post-injection Same pharmacokinetic profile. Both resist DPP-IV degradation equally Mechanism of Actio
This comparison does not assign a generated winner or score.
- Amino Acid Sequence
- 29-AA tetrasubstituted GHRH analog (D-Ala2, Gln8, Leu15, Leu27)
- Identical sequence. No structural difference
- Plasma Half-Life
- ~30 minutes post-injection
- Same pharmacokinetic profile. Both resist DPP-IV degradation equally
- Mechanism of Action
- Binds GHRH receptors in anterior pituitary, stimulates pulsatile GH release
- No mechanistic distinction. Receptor affinity and signaling pathways identical
- Common Supplier Labeling
- Marketed as 'CJC-1295 without DAC modification'
- Marketed as 'Modified GRF 1-29' to distinguish from sermorelin
- Naming reflects branding preference, not chemical difference
- Typical Use in Research
- Growth hormone secretion studies, body composition protocols
- Interchangeable in all research applications
- Professional Assessment
- Both names describe the same peptide. Sourcing decisions should prioritize purity verification and synthesis quality, not label preference
- Choose based on supplier reputation and batch testing, not nomenclature